Sage Therapeutics, Inc. (SAGE)
NASDAQ: SAGE · Real-Time Price · USD
7.79
+0.17 (2.23%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Sage Therapeutics Revenue
In the year 2024, Sage Therapeutics had annual revenue of $41.24M, down -52.30%. Sage Therapeutics had revenue of $12.82M in the quarter ending December 31, 2024, a decrease of -83.56%.
Revenue (ttm)
$41.24M
Revenue Growth
-52.30%
P/S Ratio
11.48
Revenue / Employee
$116,836
Employees
353
Market Cap
478.94M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41.24M | -45.21M | -52.30% |
| Dec 31, 2023 | 86.46M | 78.77M | 1,024.84% |
| Dec 31, 2022 | 7.69M | 1.38M | 21.85% |
| Dec 31, 2021 | 6.31M | -1.11B | -99.43% |
| Dec 31, 2020 | 1.11B | 1.11B | 16,123.06% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
SAGE News
- 20 hours ago - Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities Investigation - Accesswire
- 2 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the Investigation - Accesswire
- 4 days ago - Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 7 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Connect - Accesswire
- 9 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - Accesswire
- 11 days ago - Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 14 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Stockholders to Learn More About the Investigation - Accesswire
- 16 days ago - Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag - Seeking Alpha